Vincent Ct Mok
Professor
Medicine & Therapeutics
The Chinese University of Hong Kong
Hong Kong
Biography
Dr. Thomas WH Leung is affiliated to Medicine & Therapeutics, CUHK . Dr. Thomas WH Leung is currently providing services as Associate Professor . Dr. Thomas WH Leung has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Thomas WH Leung contributions have acclaimed recognition from honourable subject experts around the world. Dr. Thomas WH Leung is actively associated with different societies and academies. Dr. Thomas WH Leung academic career is decorated with several reputed awards and funding. Dr. Thomas WH Leung research interests include Stroke imaging, cerebral re-vascularization therapy and intracranial atherosclerosis.
Research Interest
Vascular Cognitive Impairment, Cerebral Small Vessel Disease, Mixed Dementia, Neuroimaging, Parkinson’s disease genetics and treatments
Publications
-
Vincent MOK, Velandai SRIKANTH, Yunyun XIONG, Thanh G. PHAN, Chris MORAN Shuguang CHU, Qianhua ZHAO, Winnie W.C. CHU, Adrian WONG, Zhen HONG, Xinfeng LIU, Lawrence K.S. WONG, Ding DING. Ethnicity and Cerebral Small Vessel Disease – Comparison between Chinese and White Populations. International Journal of Stroke 2014 (Impact factor 4.029)
-
Jie YANG, Adrian WONG, Zhaolu WANG, Wenyan LIU, Lisa AU, Yunyun XIONG, Winnie W.C. CHU, Eric Yim Lung LEUNG, Sirong CHEN, Christine LAU, Anne Y.Y. CHAN, Alexander Y.L. LAU, Florence FAN, Vincent IP, Yannie SOO, Thomas LEUNG, MD1; Chi Lai HO, Lawrence Ka Sing WONG, Vincent C.T. MOK.* Risk factors for incident dementia after stroke and transient ischemic attack. Alzheimer’s & Dementia 2014 March 3 (Impact factor 17.472)
-
Yunyun Xiong, Adrian Wong, Margherita Cavalieri, Reinhold Schmidt, Winnie W.C. Chu, Xinfeng Liu, Ka Sing Wong, Vincent Mok*. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities. Neurotherapeutics 2014 Apr 2 (Impact factor 5.904)
